Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2025)
Historic Free Cash Flow for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$73.0 million.
- Nurix Therapeutics' Free Cash Flow fell 4346.98% to -$73.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$263.5 million, marking a year-over-year decrease of 4487.59%. This contributed to the annual value of -$263.5 million for FY2025, which is 4487.59% down from last year.
- Per Nurix Therapeutics' latest filing, its Free Cash Flow stood at -$73.0 million for Q4 2025, which was down 4346.98% from -$60.1 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Free Cash Flow registered a high of $24.1 million during Q4 2023, and its lowest value of -$73.0 million during Q4 2025.
- In the last 5 years, Nurix Therapeutics' Free Cash Flow had a median value of -$44.1 million in 2023 and averaged -$39.9 million.
- As far as peak fluctuations go, Nurix Therapeutics' Free Cash Flow plummeted by 73941.75% in 2022, and later skyrocketed by 15948.67% in 2023.
- Nurix Therapeutics' Free Cash Flow (Quarter) stood at -$31.8 million in 2021, then decreased by 27.53% to -$40.5 million in 2022, then surged by 159.49% to $24.1 million in 2023, then plummeted by 310.99% to -$50.9 million in 2024, then plummeted by 43.47% to -$73.0 million in 2025.
- Its Free Cash Flow was -$73.0 million in Q4 2025, compared to -$60.1 million in Q3 2025 and -$65.8 million in Q2 2025.